PI for Tadalafil Dosage Patent refused in Italy

Written By

giovanni galimberti Module
Giovanni Galimberti

Partner
Italy

As well as being one of the founding partners of our Italian operations, I'm now Managing Partner and head of our Italian Intellectual Property department.

evelina marchesoni Module
Evelina Marchesoni

Senior Associate
Italy

I specialise in multi-jurisdictional contentious patent matters, with a particular focus on Life Sciences & Healthcare and the Tech & Comms sector.

By decisions dated 30 July 2018, then confirmed in the appeal by decisions dated 30 August 2018, the Court of Milan dismissed PI requested by ICOS and its licensee Eli Lilly against Sandoz, ascertaining the prima facie invalidity of the ICOS patent EP 1 173 181 for a Tadalafil dosing regimen.

Background

EP 1 173 181 (“EP ‘181”) relates to a dosage regime for the PDE5 inhibitor Tadalafil for the treatment for erectile dysfunction (ED), claiming doses of 1-5 mg of Tadalafil up to a maximum total dose of 5 mg per day.

Sandoz filed negative PI proceedings in the Court of Milan, seeking an urgent declaration of non-infringement of EP 181 by its generic tadalafil medicinal products at doses of 10 mg and 5 mg.

View the full article in our BioTalk blog.

Latest insights

More Insights
featured image

Mitigating the legal risks of licencing in open-source software and database elements

7 minutes Jun 17 2025

Read More
Curiosity line green background

SG Trade Marks Fast Programme: Accelerated Examination for Local Applications in Singapore

Jun 12 2025

Read More
featured image

What the UK-US ‘trade deal’ means for businesses on both sides of the Atlantic

7 minutes Jun 03 2025

Read More